Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
作者： J A Woyach , G Lozanski , A S Ruppert , A Lozanski , K A Blum
DOI: 10.1038/LEU.2011.375
关键词: Ataxia Telangiectasia Mutated Proteins 、 Cancer research 、 Tumor suppressor proteins 、 Protein-Serine-Threonine Kinases 、 Refractory Chronic Lymphocytic Leukemia 、 Survival rate 、 Cell Cycle Protein 、 Treatment outcome 、 Biology 、 DNA-binding protein 、 Immunology
摘要: Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated flavopiridol: impact genetic features
nature.com
sci-hub.se 参考文章(17)
E Wattel, C Preudhomme, B Hecquet, M Vanrumbeke, B Quesnel, I Dervite, P Morel, P Fenaux, p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies Blood. ,vol. 84, pp. 3148- 3157 ,(1994) , 10.1182/BLOOD.V84.9.3148.3148
Hartmut Dohner, Konstanze Fischer, Martin Bentz, Katrin Hansen, Axel Benner, Georges Cabot, Daniela Diehl, Richard Schlenk, Johannes Coy, Stephan Stilgenbauer, Martin Volkmann, Peter R Galle, Annemarie Poustka, Werner Hunstein, Peter Lichter, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood. ,vol. 85, pp. 1580- 1589 ,(1995) , 10.1182/BLOOD.V85.6.1580.BLOODJOURNAL8561580
G Juliusson, KH Robert, A Ost, K Friberg, P Biberfeld, B Nilsson, L Zech, G Gahrton, Prognostic information from cytogenetic analysis in chronic B- lymphocytic leukemia and leukemic immunocytoma Blood. ,vol. 65, pp. 134- 141 ,(1985) , 10.1182/BLOOD.V65.1.134.134
JR Neilson, R Auer, D White, N Bienz, JJ Waters, JA Whittaker, DW Milligan, CD Fegan, Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival Leukemia. ,vol. 11, pp. 1929- 1932 ,(1997) , 10.1038/SJ.LEU.2400819
Christopher Fegan, Paul Moss, Tatjana Stankovic, Belinda Austen, Judith E. Powell, Azra Alvi, Ian Edwards, Laura Hooper, Jane Starczynski, A. Malcolm R. Taylor, Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL Blood. ,vol. 106, pp. 3175- 3182 ,(2005) , 10.1182/BLOOD-2004-11-4516
John C Byrd, Thomas S Lin, James T Dalton, Di Wu, Mitch A Phelps, Beth Fischer, Mollie Moran, Kristie A Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J Schaaf, Amy J Johnson, David M Lucas, Nyla A Heerema, Gerard Lozanski, Donn C Young, Jose-Ramon Suarez, A Dimitrios Colevas, Michael R Grever, None, Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. ,vol. 109, pp. 399- 404 ,(2007) , 10.1182/BLOOD-2006-05-020735
Judith Dierlamm, Lucienne Michaux, Arnold Criel, Iwona Wlodarska, Herman Van Den Berghe, Dieter Kurt Hossfeld, Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications Cancer Genetics and Cytogenetics. ,vol. 94, pp. 27- 35 ,(1997) , 10.1016/S0165-4608(96)00246-4
Rong Chen, Michael J. Keating, Varsha Gandhi, William Plunkett, Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. ,vol. 106, pp. 2513- 2519 ,(2005) , 10.1182/BLOOD-2005-04-1678
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, TP53 Mutation and Survival in Chronic Lymphocytic Leukemia Journal of Clinical Oncology. ,vol. 28, pp. 4473- 4479 ,(2010) , 10.1200/JCO.2009.27.8762
Chris Pepper, Thet Thet Lin, Guy Pratt, Saman Hewamana, Paul Brennan, Louise Hiller, Robert Hills, Rachel Ward, Jane Starczynski, Belinda Austen, Laura Hooper, Tatjana Stankovic, Chris Fegan, Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers Blood. ,vol. 112, pp. 3807- 3817 ,(2008) , 10.1182/BLOOD-2008-05-157131